word count: 249 Figures: 1 Tables: 3 ABSTRACT Objective: We aimed to determine the association between autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well as markers of CV risk in the general population. Methods: Cross-sectional data were obtained from 6649 subjects (age 52.6±10.7 years, 47.4% male) of the population-based CoLaus study. CVD was defined as myocardial infarction, angina pectoris, percutaneous revascularization or bypass grafting for ischemic heart disease stroke or transient ischemic attack, and was assessed according to standardized medical records. Anti-apoA-1 IgG and biological markers were measured by ELISA and conventional automated techniques, respectively. Results: Prevalence of high anti-apoA-1 IgG in the general population was 19.9%. Presence of anti-apoA-1 IgG was significantly associated with CVD [odds ratio 1.34, 95% confidence interval (1.05-1.70), p=0.018], independently of established CV risk factors (CVRFs) including age, sex, hypertension, smoking, diabetes, low and high-density lipoprotein cholesterol levels.
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INTRODUCTION
Despite considerable advances having been made in its prevention, diagnosis and treatment, cardiovascular disease (CVD) remains the leading cause of death in the Western world. Major discoveries in the pathophysiology of CVD over the last 30 years have shifted the long-standing paradigm that held CVD primarily as a lipid-related metabolism disorder, to the current view of an immune-mediated inflammatory disease, where humoral autoimmunity may play an important role. (1, 2) Different lines of evidence indicate that autoantibodies may represent a novel, independent cardiovascular risk factor (CVRF), (3) (4) (5) not only in their potential role as biomarkers for risk stratification but also as mediators of CVD, amenable to targeted therapeutic strategies. (6) Among autoantibodies possibly related to CVD, those directed against apolipoprotein A-1 (anti-apoA-1 IgG), the major protein fraction of high-density lipoproteins (HDL), are of particular interest. During the last decade, numerous translational studies have examined the mechanisms underpinning the role of anti-apoA-1 IgG in inflammation (7, 8) and atherogenesis. (9) (10) (11) (12) In addition, preliminary clinical studies have shown encouraging results regarding the association and prognostic value of anti-apoA-1 IgG for CVD in subjects with autoimmune diseases, (9-11, 13, 14) subjects at high CV risk, (15) (16) (17) or in secondary prevention. (18-23) Nevertheless, the prevalence of anti-apoA-1 IgG and their association with CVD or markers of CV risk in the general population have not yet been examined. Therefore, the purpose of our current study was manifold: first, to investigate the prevalence and association of anti-ApoA-1 IgG with CVD in the general population. The second objective was to study the possible association of anti-ApoA-1 IgG with both established and emergent CV markers, in the general and secondary prevention populations. The third objective was to investigate the possible connexion between anti-apoA-1 IgG and serum magnesium concentrations, as anti-ApoA-1 IgG have shown to be associated with a higher basal heart rate after MI (23) through activation of Ltype calcium channels, (24, 25) tightly regulated by intracellular magnesium concentrations. (26)
MATERIALS AND METHODS

Study population and design
We obtained cross-sectional clinical and biological data from the CoLaus study, a population- Blood pressure and heart rate were measured three consecutive times using an automated sphygmomanometer (Omron® HEM-907, Matsusaka, Japan) and the average of the last two measurements was used. Hypertension was defined as a systolic blood pressure (SBP) ≥ 140 mmHg and/or a diastolic blood pressure (DBP) ≥ 90 mmHg and/or presence of anti-hypertensive treatment. Diabetes mellitus was defined as fasting plasma glucose ≥7.0 mmol/L and/or oral or insulin antidiabetic treatment. Body weight was measured in kilograms to the nearest 0.1 kg using a Seca® scale (Hamburg, Germany) and height was measured to the nearest 5 mm using a Seca® height gauge (Hamburg, Germany). Body mass index (BMI) was defined as weight/height 2 . Metabolic syndrome was identified according to the NCEP-ATP III criteria (28) in subjects presenting with at least 3 of the following components: 1) SBP>130 mm Hg or DBP>85 mm Hg or treatment; 2) waist size>88 cm if female or >102 cm if male; 3) HDL-C<1.30 mmol/L for women or <1.03 mmol/L for men; 4) TG>1.7 mmol/L or lipid-lowering drug treatment; and 5) glucose>5.6 mmol/L or antidiabetic drug treatment. Aggregate CV risk was assessed using the Systematic COronary Risk Evaluation (SCORE) algorithm. Autoimmune disease was defined as history of rheumatoid arthritis or systemic lupus erythematosus, independently of treatment status.
Prevalent CVD was defined by the presence of myocardial infarction; angina pectoris; percutaneous revascularization or bypass grafting for ischemic heart disease; stroke or transient ischemic attack and assessed according to standardized medical records. (27) A venous blood sample (50 ml) and a spot urine sample were collected from each participant under fasting conditions. The analytical procedures and clinical assays used for determining serum and urine biological markers are available in Supplemental Table I where SCr= plasma creatinine concentration in mg/dL, and age= years.
Assessment of autoantibodies against apolipoproteinA-1
Anti-apoA-1 IgG were measured as previously described, (20, 21) using the CoLaus study (2003) (2004) (2005) (2006) serum aliquots that had been previously frozen and stored at -80 °C. Maxisorp plates (Nunc TM , Denmark) were coated with purified, human-derived delipidated apolipoprotein A-1 (20 μg/ml; 50 μl/well) for 1h at 37°C. After being washed, all wells were blocked for 1h with Elevated levels of anti-apoA-1 IgG were set at an OD cut-off of OD>0.64, corresponding to the 97.5 th percentile of a reference population of 140 healthy blood donors. In order to limit the impact of inter-assay variation, we calculated an index consisting in the ratio between sample net absorbance and the positive control net absorbance x 100. The index value corresponding to the 97.5 th percentile of the normal distribution was 37. Accordingly, to be considered as positive (presenting elevated anti-apoA-1 IgG levels), samples had to display both an absorbance value >0.64 OD and an index value ≥37.
Sample size and power calculation
Based on previous published studies on healthy blood donors (21) we assumed an expected prevalence of anti-apoA-1 IgG in healthy subjects devoid of CVD of 5-10%. Taking into account the CVD rate in CoLaus (455 events or 6.8%) and a two-sided alpha of 5%, our study had 80% power to detect an odds ratio (OR) of anti-apoA-1 IgG for CVD at OR=1.51.
Statistical analysis
Univariate analysis of continuous variables was performed using the student's t-test or the nonparametric Mann-Whitney test to account for non-parametric distributions, and results were expressed as mean ± standard deviation (SD) or as median (interquartile range), as appropriate.
Analysis of discrete variables was performed using chi-square test and results were expressed as number of participants and (percentage).
Multivariate analysis was performed using logistic regression adjusting for age, sex, hypertension, diabetes, smoking, low-density (LDL) and high-density lipoprotein cholesterol (HDL). Results were expressed as OR and 95% confidence interval (CI). All analyses were performed using STATA 13.0 (Stata Corp, College Station, Texas, USA). A two-tailed p<0.05 was considered statistically significant.
RESULTS
Association between anti-apoA-1 IgG and CVD, independently of established CVRF
The flowchart and objectives of the study are summarized in Figure 1 . N=6194 (93.2%) study participants were devoid of baseline CVD (primary prevention subgroup), while n=455 (6.8%) were in secondary prevention. The distribution of raw optical density (OD) values for anti-apoA-1 IgG in the sample is illustrated in Supplemental Figure I. Table 1 , elevated levels of anti-apoA-1 IgG were present in 1323 out of 6649 (19.9%) study subjects. In the general population, the prevalence of clinical CVRF did not differ between subjects with presence vs. absence of anti-apoA-1 IgG. The same observation was true both in the primary and the secondary prevention subgroups. Furthermore, we did not find any significant difference in CV drugs rates depending on presence vs. absence of anti-apoA-1 IgG.
As described in
Among study subjects, n=154 had a history of autoimmune disease (either rheumatoid arthritis or systemic lupus erythematosus). We observed no association between history of autoimmune disease and elevated levels of anti-apoA-1 IgG in the population ( Table 1) .
Prevalence of CVD in the general population was significantly associated with presence vs
absence of anti-ApoA-1 IgG (8.3% vs. 6.5% respectively, p=0.018). Indeed, patients with history of CVD had higher median OD values for anti-ApoA-1 IgG than subjects without (OD: 0.412, interquartile range (IQR): 0.273 -0.661 vs. 0.395, IQR: 0.253 -0.589, p=0.029).
Translated into odds ratio, elevated levels of anti-ApoA-1 IgG were associated with a 1.3-fold increased risk for prevalent CVD; an association which remained unchanged after adjustment for established CVRFs, including age, sex, hypertension, diabetes, smoking, LDL and HDL cholesterol. Alternatively, there was a 15% risk increase for prevalent CVD per standard deviation increase in anti-apoA-1 IgG values, which was also independent of established CVRFs (Table 2) . Finally, the association between presence of anti-apoA-1 IgG and CVD in the multivariate model remained unchanged after further adjusting for history of autoimmune disease as well as after excluding subjects with history of autoimmune disease (n=154) from the analysis. Table 3 summarizes variations in biological markers of CV risk, according to presence or absence of anti-apoA-1 IgG.
Association between anti-apoA-1 IgG levels and biological markers of CV risk
Subjects with elevated anti-ApoA-1 IgG levels tended to have lower serum levels of total cholesterol, HDL and magnesium than patients with low anti-apoA-1 IgG levels. No trends or significant differences were observed for other lipid parameters, renal function, hs-CRP or uric acid between these two groups. Inverse and significant Spearman correlations were retrieved for anti-apoA-1 IgG and total cholesterol as well as anti-apoA-1 IgG and magnesium levels both in the general population (r=-0.05, p<0.001; r=-0.06, p<0.001, respectively) and in the primary prevention subgroup (r=-0.05, p<0.001; r=-0.05, p<0.001, respectively).
In the secondary prevention subgroup, patients with elevated anti-apoA-1 IgG levels presented significantly lower HDL and magnesium values, but higher hs-CRP and uric acid values than patients with low anti-apoA-1 IgG levels (Table 3) . Additionally, inverse significant Spearman correlations were observed between anti-apoA-1 IgG and HDL (r=-0.10, p=0.03) or anti-apoA-1
IgG and magnesium levels (r=-0.19; p<0.001), while significant positive correlations were found between anti-apoA-1 IgG and hs-CRP levels (r=0.11, p=0.02). The correlation for anti-apoA-1
IgG and uric acid levels was also positive (r=0.09; p=0.05). No other significant correlations were observed between anti-apoA-1 IgG levels and biological parameters (data not shown). Notably, the negative association between anti-apoA-1 IgG and HDL levels remained robust after adjusting for statin treatment. Furthermore, no overall difference in the fractional excretion of magnesium in urine was found between subjects with presence vs. absence of anti-apoA-1 IgG, either in the general population or in the primary or secondary prevention subgroups (data not shown).
In a subgroup analysis performed specifically on coronary heart disease (CHD) patients (n=235), subjects with elevated anti-apoA-1 IgG levels were more likely to present with metabolic syndrome and a higher basal heart rate when compared to patients with low anti-apoA-1 IgG levels ( Supplemental Table II ). Elevated levels of anti-apoA-1 IgG were also associated with significantly lower HDL and magnesium levels (p=0.015, p=0.004 respectively), and increased triglyceride (p=0.01) and hs-CRP levels (p=0.005) ( Supplemental Table III ).
DISCUSSION
The main finding of the present large-scale study is the novel association between anti-apoA-1
IgG and CVD in a population-based sample, which is independent of established CVRF. Our results validate initial reports, which suggested that presence of these autoantibodies could be associated with prevalent CVD, (14, 18) as well as CV complications in rheumatoid arthritis patients (13) and in high CV risk populations. (19, 22, 23) Furthermore, in this study we confirm that the presence of elevated anti-apoA-1 IgG levels in secondary prevention patients is associated with a pro-inflammatory systemic profile, (7-9, 13, 14, 22) as reflected by lower HDL concentrations, but higher hs-CRP and uric acid levels. While different studies previously reported anti-apoA-1 IgG presence being associated with a loss of anti-atherogenic properties of HDL in specific settings, (9) (10) (11) (12) this study is the first to indicate that elevated anti-apoA-1 IgG levels are inversely associated with HDL levels in subjects with established CVD, and remain so independently of statin treatment.
Because anti-apoA-1 IgG target the major protein component of HDL, the association between anti-apoA-1 IgG and lower HDL levels may be related to the clearance of immune anti-apoA-1 IgG and HDL complexes by the reticular-endothelial system. In accordance with this hypothesis, human case reports (30) reported that patients with high anti-apoA-1 IgG levels entirely lacked mature HDL particles, suggesting decreased ability of pre-beta HDL to become lipidated. Along the same line, in a murine model of SLE, anti-apoA-1 IgG could lower HDL levels without affecting hepatic HDL biosynthesis, possibly by accelerating HDL clearance.(12) On the other hand, anti-apoA-1 IgG passive immunization in mice has not shown to impact HDL levels, despite otherwise marked effects on atherogenesis, myocardial necrosis and survival, (8, 20) leaving the question open as to whether a causal link between apoA-1 IgG and HDL levels does exist. Lastly, the presence of these antibodies may also contribute to loss of HDL function by impairing ATP-binding cassette transporter A1 (ABCA1)-mediated cholesterol efflux or interfering with paraoxonase 1 (PON1) activity, although this assumption requires further experimental validation. (9) (10) (11) (12) 
Association between anti-apoA-1 IgG levels and biological markers of CV risk
The fact that patients with high anti-apoA-1 IgG levels had higher hs-CRP levels than patients without anti-apoA-1 IgG is in line with previous studies showing that elevated anti-apoA-1 IgG levels were associated with higher circulating levels of pro-inflammatory cytokines, including IL-6, TNF-alpha, myeloperoxidase, hs-CRP and matrix-metalloproteinase 9. (7, 13, 17, 20, 22) Because endotoxin-free anti-apoA-1 IgG was shown to induce a dose-dependent production of IL-6 and other inflammatory cytokines by human macrophages in a TLR2/CD14 dependent manner, (7) a straightforward explanation for this association could be that the anti-apoA-1 IgGdriven production of IL-6 by macrophages directly induces CRP production by hepatocytes, a phenomenon highly dependent on IL-6 stimulus. (31, 32)
Another compelling finding of our study was that patients with high anti-apoA-1 IgG levels had significantly lower serum magnesium concentrations compared to patients with low anti-apoA-1 IgG levels. Previous studies showed anti-apoA-1 IgG to elicit in vitro a sustained positive chronotropic response on cardiomyocytes through the activation of L-type calcium channels, (24, 25) the activity of which is enhanced by intracellular magnesium deficiency. (26) Since magnesium depletion predisposes for cardiac arrhythmias and CHD, (33) this descriptive association could provide a model to support our previous observation that showed elevated anti-apoA-1 IgG levels after myocardial infarction to be associated with a higher basal heart rate, as assessed by Holter monitoring. (23) Interestingly, in the present study -apart from the difference in circulating concentrations of magnesium not previously assessed (23) -we found the same association between elevated anti-apoA-1 IgG levels and basal heart rate in the subgroup of CHD patients. It is therefore plausible that the higher basal heart rate observed in CHD patients with elevated anti-apoA-1 IgG levels could be mediated by concomitant lower magnesium concentrations, or that these patients have increased chronotropic susceptibility to relative hypomagnesaemia. Since the fractional excretion of magnesium did not differ between subjects with high vs. low anti-apoA-1 IgG levels, one can reasonably exclude urinary magnesium wasting as the cause of this finding.
Strengths and limitations
The strength of our study lies in its unbiased, community-based approach that enabled us to confirm that elevated anti-apoA-1 IgG are independently associated with CVD in a large and extensively characterized sample of the general population.
There are several limitations to this study. First, owing to the cross-sectional nature of the data, a causal relationship between anti-ApoA-1 IgG and CVD cannot be firmly established. This hypothesis is currently being tested in an ongoing longitudinal study aiming at exploring the prognostic value of anti-ApoA-1 IgG in the general population.
Secondly, we did not measure apoA-1 levels nor did we assess the possible qualitative changes in HDL, such as PON1 activity, reverse cholesterol efflux capacity or HDL anti-inflammatory properties. As apoA-1 is largely responsible for reverse cholesterol transport and stabilization of PON1, (34) it is plausible that anti-apoA-1 IgG could decrease apoA-1 levels, rendering the protein less able to promote cholesterol efflux and thereby manifest its anti-atherogenic effects.
We assume that both apoA-1 levels and HDL functional properties would be altered in anti-apoA-1 IgG positive patients, as reported earlier; (11) however, we did not collect data to challenge this hypothesis.
Thirdly, it remains elusive as to whether elevated anti-apoA-1 IgG levels are associated with susceptibility to infections. Previous studies reported that polyclonal human anti-apoA-1 IgG response is focused against epitopes present on the C-terminal part of apoA-1. (35, 36) Since the latter shares structural homologies with TLR2, (7) it is suggested that pathogen molecular mimicry may be the underlying mechanism for the deleterious properties of these autoantibodies. The design of this study did not allow for the exploration of association between the existence of anti-apoA-1 IgG and previous exposure to specific pathogens.
CONCLUSION
The present study confirms that elevated anti-apoA-1 IgG levels are independently associated with CVD in the general population, while also being associated with CV biomarkers in patients with a history of CVD. Prospective studies are needed to evaluate the prognostic value of anti-apoA-1 IgG as a biomarker for CVD in the general population as well as to investigate the possible therapeutic value of developing immune therapies directed against anti-apoA-1 IgG.
17.
Wick • Small-scale clinical studies have shown promising results regarding the association and prognostic value of autoantibodies against apolipoprotein A-1 for cardiovascular disease in subjects with autoimmune diseases, subjects at high CV risk or following myocardial infarction.
What this paper adds
• This is the first study to demonstrate that autoantibodies against apolipoprotein A-1 are significantly associated with prevalent cardiovascular disease in the general population, independently of established cardiovascular risk factors.
• Our results suggest that autoantibodies against apolipoprotein A-1 may prove useful as a novel biomarker as well as a potential target for specific immune modulation strategies for cardiovascular disease. 
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